About

Fahmeedah Kamal is a Clinical Associate Professor of Medicine in the Nephrology department at Stanford Medicine. Her professional focus is on nephrology, with particular expertise in glomerulonephritis and kidney disease. She holds medical degrees from the University of Missouri Kansas City School of Medicine and completed her fellowship in Nephrology at Brown University Department of Nephrology. Dr. Kamal is also certified by the American Board of Internal Medicine in both Internal Medicine and Nephrology. Her roles include serving as the Medical Director of the Quality Improvement program since 2018, the Medical Director of the Satellite Menlo Park Dialysis Unit since 2016, and a member of the Medical Professional Practice Evaluation Committee since 2016. Her clinical practice is primarily based at the Stanford Nephrology Clinic in Palo Alto, California. Her research interests include biomarkers of kidney diseases such as IgA nephropathy, and she has contributed to scholarly work on the pathophysiology and prognosis of glomerular diseases. Dr. Kamal's work emphasizes early diagnosis and treatment of kidney conditions, integrating clinical practice with ongoing research in nephrology.

Research topics

• Medicine
• Urology
• Internal medicine
• Intensive care medicine
• Emergency medicine
• Endocrinology
• Gastroenterology
• Pathology

Selected publications

• Current trial landscape of IgA nephropathy therapy

  Med · 2026-01-01 · 1 citations

  article
  PublisherDOI

• How should we best manage the consequences of nephron loss in IgAN?

  Nephrology Dialysis Transplantation · 2025-10-27 · 1 citations

  articleOpen access

  IgA nephropathy often presents with chronic nephron loss and clinical chronic kidney disease. It is thus important that non IgA specific interventions are deployed to help sustain kidney function and structure. This review details interventions in lifestyle and medications that exist and are arising to best meet this important challenge.

  PublisherDOI

• Kappa-Restricted IgA Nephropathy Treated Successfully With Targeted-Release Budesonide

  Kidney International Reports · 2025-11-29

  articleOpen access
  PublisherOA PDFDOI

• Current Biomarkers of IgA Nephropathy

  Seminars in Nephrology · 2024-09-01 · 5 citations

  review1st authorCorresponding
  PublisherDOI

• Considering the Treatment of IgA Nephropathy

  Clinical Journal of the American Society of Nephrology · 2023-08-03

  letterOpen accessSenior author

  Division of Nephrology, Stanford University Medical Center, Stanford, California Correspondence: Dr. Richard A. Lafayette. Division of Nephrology, Stanford University, 300 Pasteur Drive, Stanford, CA 94025. Email: [email protected] See related Patient Voice, "Selecting Treatment for IgA Nephropathy," and article, "Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting," on pages 1109–1110 and 1186–1194, respectively.

  PublisherOA PDFDOI

• Conserving Water and Dialysate During Inpatient Dialysis Sessions

  Journal of the American Society of Nephrology · 2022

  • Medicine
  • Intensive care medicine
  • Emergency medicine

  Background: Assessing hemodialysis adequacy for inpatients remains poorly understood. The applicability of outpatient targets such as the urea reduction ratio (URR) to inpatients has not been systematically studied, yet is a marker measured in our hospital. Furthermore, the average baseline dialysate flow rate employed in our institution exceeds the rate that is sufficient to achieve adequate dialysis per guidelines. Patients receiving hemodialysis have their URR measured when our nurses anticipate they will remain longer than 3 sessions. Our current practice is to prescribe a standard dialysate flow rate of 700ml/min for all established patients. We aimed to improve the quality of our inpatient dialysis unit by educating providers about the conservation benefits of dialysate flow rates that can be employed without any decrement to the adequacy of dialysis treatments. Methods: We educated prescribing providers of the minimal impact of a Qd exceeding 1.5 times the Qb on measured URR, and proposed that a new universal standard of 600ml/min be implemented. Providers maintained the ability to prescribe any dialysate flow rate they felt appropriate for the patient. Measurements of URR continued as per standard dialysis practice. Data from one month prior to and after the education intervention were reviewed. Results: In the one month preceding the intervention, 49 dialysis sessions had a measured URR, and there were 44 sessions in the month immediately after. The average pre-BUN, post-BUN, blood flow rate and treatment time were not statistically different. The prescribed average dialysate flow rate was 686ml/min pre-intervention and 620ml/min post-intervention (p = 0.000002). Despite this, there was no statistically significant difference in measured URR (p = 0.19). The average used dialysate volume per session decreased from 138L to 130L (p = 0.04). Conclusions: Decreasing the standard dialysate flow rate for acute inpatients had no impact on measured URR. While this confers modest dialysate concentrate and water savings per patient, the net effect of multiple daily sessions over a prolonged period of time offers important conservation benefits to any dialysis unit.

  PublisherDOI

• Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

  Kidney International · 2022 · 210 citations

  • Medicine
  • Urology
  • Internal medicine
  DOI

• Updates in Management and Timing of Dialysis in Acute Kidney Injury

  Journal of Hospital Medicine · 2019-02-20 · 2 citations

  reviewOpen access

  Acute kidney injury (AKI) is a common complication in hospitalized patients and is associated with mortality, prolonged hospital length of stay, and increased healthcare costs. This paper reviews several areas of controversy in the identification and management of AKI. Serum creatinine and urine output are used to identify and stage AKI by severity. Although standardized definitions of AKI are used in research settings, these definitions do not account for individual patient factors or clinical context which are necessary components in the assessment of AKI. After treatment of reversible causes of AKI, patients with AKI should receive adequate volume resuscitation with crystalloid solutions. Balanced crystalloid solutions generally prevent severe hyperchloremia and could potentially reduce the risk of AKI, but additional studies are needed to demonstrate a clinical benefit. Intravenous albumin may be beneficial in patients with chronic liver disease either to prevent or attenuate the severity of AKI; otherwise, the use of albumin or other colloids (eg, hydroxyethyl starch) is not recommended. Diuretics should be used to treat volume overload, but they do not facilitate AKI recovery or reduce mortality. Nutrition consultation may be helpful to ensure that patients receive adequate, but not excessive, dietary protein intake, as the latter can lead to azotemia and electrolyte disturbances disproportionate to the patient's kidney failure. The optimal timing of dialysis initiation in AKI remains controversial, with conflicting results from two randomized controlled trials.

  PublisherOA PDFDOI

Frequent coauthors

• Zhaohui Ni

  Shanghai Jiao Tong University

  2 shared

• Alexander Paliege

  University Hospital Carl Gustav Carus

  2 shared

• Sean Barbour

  University of British Columbia

  2 shared

• Hong Zhang

  2 shared

• Daniel Cattran

  University of Toronto

  2 shared

• Shaomei Li

  2 shared

• Jürgen Floege

  RWTH Aachen University

  2 shared

• Hernán Trimarchi

  Hospital Británico de Buenos Aires

  2 shared